Exscientia - Model EXS21546 - Peripherally-Restricted and Selective Antagonist Drug - Brochure

EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell activation.